Azathioprine and diffuse alveolar haemorrhage: The pharmacogenetics of thiopurine methyltransferase

European Respiratory Journal

Volumn 30, Issue 5, 2007, Pages 1014-1017

  Perri, D ^a,c,d   Cole, D E C ^a,b   Friedman, O ^b   Piliotis, E ^b   Mintz, S ^b   Adhikari, N K J ^b,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Azathioprine; Diffuse alveolar haemorrhage; Myelotoxicty; Pharmacogenetics; Polymorphism; Thiopurine methyltransferase

Indexed keywords

AZATHIOPRINE; PREDNISONE; THIOPURINE METHYLTRANSFERASE;

AGED; ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEBRILE NEUTROPENIA; FIBEROPTIC BRONCHOSCOPY; FIBROSING ALVEOLITIS; HUMAN; LUNG HEMORRHAGE; LUNG LAVAGE; MALE; PANCYTOPENIA; PHARMACOGENETICS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; THORAX RADIOGRAPHY;

AZATHIOPRINE; FEMALE; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; MALE; METHYLTRANSFERASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PULMONARY FIBROSIS;

EID: 38849141668     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00026107     Document Type: Article

References (29)

1. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517-525.
2. du Bois RM. Is idiopathic pulmonary fibrosis now treatable? Am J Respir Crit Care Med 2005; 171: 939-940.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
4. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-339.
5. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 567-572.
6. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-614.
7. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89-98.
8. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-417.
9. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine and azathioprine. J Clin Oncol 2001; 19: 2293-2301.
10. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3: Suppl. 1, S30-S38.
11. Dervieux T, Matsutani M, Barry M, Siedman E. Drug metabolite monitoring of azathioprine/6-MP therapy: contribution of thiopurine methyltransferase gene polymorphisms: 69. Ther Drug Monit 2005; 27: 228.
12. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Int Med 1998; 129: 716-718.
13. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of the thiopurine S-methyltransferase gene in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-1030.
14. Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatease gene mutations predicts myelosuppresion in IBD patients treated with azathioprine. Gastroenterology 2004; 126: Suppl. 2, A112.
15. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 181-187.
16. Fabre MA, Jones DC, Bunce M, et al. The impact of thiopurine s-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation. Transpl Int 2004; 17: 531-539.
17. Anstey AV, Wakelin S, Reynolds NJ, British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004; 151: 1123-1132.
18. Van Aken J, Schmedders M, Feurerstein G, Kollek R. Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am J Pharmacogenomics 2003; 3: 149-155.
19. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphisms. Pharmacogenetics 2002; 12: 421-423.
20. Marra CA, Esdaile JM, Anis AH. Practical Pharmacogenetics: The cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29: 2507-2512.
21. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 593-599.
22. Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006; 24: 767-781.
23. van den Akker-van Marle ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006; 7: 783-792.
24. Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42: 628-632.
25. Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006; 53: 399-404.
26. Sayani FA, Prosser C, Bailey RJ, Jacobs P, Fedorak RN. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can J Gastroenterol 2005; 19: 147-151.
27. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: V1-V16.
28. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-1385.
29. Luppi F, Cerri S, Beghe B, Fabbri LM, Richeldi L. Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. Respir Med 2004; 98: 1035-1044.